For Agitation in Alzheimer Disease, a Novel, Oral NMDA Receptor Antagonist Could be the Next Targeted Treatment
"One of the good things about is that it's not an antipsychotic, so it's not going to have the boxed...
Antagonist
"One of the good things about is that it's not an antipsychotic, so it's not going to have the boxed...
